Rosebud Biosciences vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Rare disease drug discovery using patient-derived organoids and robotics to screen therapeutics matching real genetic mutations; YC and NSF backed with Stanford-validated pediatric heart disease breakthrough.
About
Rosebud Biosciences is a San Carlos-based drug discovery company that accelerates therapeutic development for rare diseases by screening drug candidates against patient-derived organoids — miniature 3D organ models grown from patients' own cells with matching genetic mutations — using robotic automation and machine learning to identify compounds that correct disease phenotypes at a scale impossible with traditional cell line testing. Founded in 2020 and backed by Y Combinator, NSF, and other investors with $440,000 in revenue, Rosebud has achieved Stanford-validated research breakthroughs published in prestigious scientific journals, including discovering a novel drug target for pediatric heart disease.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.